Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016
Published Jun 15, 2016
131 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia)
- The report reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics and enlists all their major and minor projects
- The report assesses Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding t

  
Source:
Document ID
GMDHC8171IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Anemia in Chronic Kidney Disease (Renal Anemia) Overview101
Therapeutics Development111
  Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) Overview111
Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutics under Development by Companies123
Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline Products Glance154
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
  Unknown Stage Products181
Anemia in Chronic Kidney Disease (Renal Anemia) Products under Development by Companies192
Anemia in Chronic Kidney Disease (Renal Anemia) Companies Involved in Therapeutics Development2127
  3SBio Inc.211
  Acceleron Pharma, Inc.221
  Akebia Therapeutics, Inc.231
  Amgen Inc.241
  Bayer AG251
  BIOCAD261
  CCM Duopharma Biotech Bhd.271
  Chong Kun Dang Pharmaceutical Corp.281
  CJ HealthCare Corp.291
  Daiichi Sankyo Company, Limited301
  Dr. Reddy's Laboratories Limited311
  Eli Lilly and Company321
  FibroGen, Inc.331
  GlaxoSmithKline Plc341
  Intas Pharmaceuticals Ltd.351
  Japan Tobacco Inc.361
  JCR Pharmaceuticals Co., Ltd.371
  Jiangsu Hansoh Pharmaceutical Co., Ltd.381
  LG Life Science LTD.391
  Medgenics, Inc.401
  Myungmoon pharmaceutical Co., Ltd.411
  Panacea Biotec Limited421
  Pfizer Inc.431
  PharmaEssentia Corporation441
  Pieris Pharmaceuticals, Inc.451
  Sandoz International GmbH461
  Zydus Cadila Healthcare Limited471
Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutics Assessment489
  Assessment by Monotherapy Products481
  Assessment by Target492
  Assessment by Mechanism of Action512
  Assessment by Route of Administration532
  Assessment by Molecule Type552
Drug Profiles5759
  daprodustat Drug Profile572
  darbepoetin alfa Drug Profile593
  darbepoetin alfa Drug Profile621
  darbepoetin alfa Drug Profile631
  darbepoetin alfa Drug Profile641
  darbepoetin alfa Drug Profile651
  darbepoetin alfa Drug Profile661
  darbepoetin alfa Drug Profile671
  darbepoetin alfa Drug Profile681
  darbepoetin alfa Drug Profile691
  DS-1093 Drug Profile701
  EPO-018B Drug Profile711
  epoetin alfa Drug Profile722
  epoetin alfa Drug Profile741
  epoetin zeta Drug Profile753
  FG-2216 Drug Profile782
  JTZ-951 Drug Profile801
  LBDE Drug Profile811
  LY-3113593 Drug Profile821
  MDGN-201 Drug Profile832
  MMP-0101 Drug Profile851
  molidustat Drug Profile862
  P-1116 Drug Profile881
  PEG-EPO Drug Profile891
  Peg-EPO Drug Profile901
  PEG-EPO Drug Profile911
  PRS-080 Drug Profile923
  Recombinant Protein for Renal Anemia Drug Profile951
  roxadustat Drug Profile967
  Small Molecule to Inhibit HIF-PH for Renal Anemia Drug Profile1031
  sotatercept Drug Profile1045
  SSS-06 Drug Profile1091
  vadadustat Drug Profile1106
Anemia in Chronic Kidney Disease (Renal Anemia) Dormant Projects1161
Anemia in Chronic Kidney Disease (Renal Anemia) Discontinued Products1171
Anemia in Chronic Kidney Disease (Renal Anemia) Product Development Milestones11812
  Featured News &Press Releases1181
    May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction1181
    May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat1181
    Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings1191
    Apr 08, 2016: Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's nephrology indication1191
    Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat1201
    Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease1202
    Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program1221
    Oct 28, 2015: Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting1232
    Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia1251
    Jul 15, 2015: Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis1251
    May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress1261
    Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN1262
    Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat1281
    Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease1281
    Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-2011291
Appendix1302
  Methodology1301
  Coverage1301
  Secondary Research1301
  Primary Research1301
  Expert Panel Validation1301
  Contact Us1301
  Disclaimer1311

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anemia-in-Chronic-Kidney-Disease-Renal-Anemia-Pipeline-Review-H1-2016-2088-15941>
  
APA:
Global Markets Direct - Market Research. (2016). Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anemia-in-Chronic-Kidney-Disease-Renal-Anemia-Pipeline-Review-H1-2016-2088-15941>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.